Re: RVXOT

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: RVXOT

in response to

Re: RVXOT

RVXoldtimer

posted on May 06, 2020 09:21AM

RVXOT does the following link makes any sense to you?

https://www.theglobeandmail.com/investing/markets/stocks/ZENI-P-X/

Note the description:

"DESCRIPTION

Zenith Capital Corp is a clinical stage biotechnology company. It develops bromodomain and extraterminal domain protein (BET) inhibitors for the treatment of cancer and other disorders with unmet medical need. Its pipeline product ZEN-3694, will help for the treatment of metastatic castration resistant prostate cancer."